A possible tie-up between Bristol Myers Squibb and AstraZeneca might seem like a long shot to Wall Street skeptics, but the market's enthusiasm around a potential deal points toward a broader trend that can't be ignored.
Mergers and acquisitions in the biopharmaceutical sector have reached a fever pitch. Through early June, total capital deployed surpassed $106 billion across 201 transactions so far this year, PitchBook data show. A few things are keeping the deal train going, but the most notable is the looming expiration of key patent protections, leaving older drugs vulnerable to competition from generics and "copycat" biosimilars.
"M&A is just such a big part of the ethos in pharma right now, and our expectation is that momentum is going to continue," Goldman Sachs analyst Asad Haider told Barron's.
While most of this year's deals were relatively smaller-scale acquisitions of biotechs, several transactions have stood out: GSK's $10.6 billion acquisition of Nuvalent; Sun Pharmaceutical Industries' planned $11.75 billion purchase of Organon; and Eli Lilly's ongoing buying spree, capped off by a July deal to acquire AtaiBeckley.
Investors could have another major transaction to add to the list. AstraZeneca and Bristol Myers Squibb have held early merger talks, according to a report. Neither company has commented publicly. An AstraZeneca spokesperson declined to comment and Bristol Myers Squibb didn't respond to a request for comment from Barron's.
If a deal came to fruition, it would rank among the largest in industry history, overtaking Bristol Myers's $74 billion acquisition of Celgene in 2019. The combined company would likely have a market value around $400 billion, trailing behind only Eli Lilly, Johnson & Johnson, and AbbVie.
That is, if a deal is even in the cards. Barclays analysts say a deal is unlikely in the near term, partly because neither company has commented. Moreover, it is tough to see how this happens ahead of critical data readouts for Bristol Myers in the coming year, analysts noted Monday.
But the excitement around a possible merger is just the latest sign that M&A activity in the broader biopharma sector is taking a front seat -- and that's good for pharma stocks and shareholders themselves. When a company as large as Bristol Myers can be a takeover target, everyone in the sector gets a takeover premium baked into their valuation.
"Large companies are signaling an appetite to continue to make deals," Goldman's Haider said. "That includes companies like Eli Lilly and AbbVie that aren't sitting on the cusp of a patent cliff."
Sustained M&A activity also offers a reliable tailwind for the broader biopharma space. A steady clip of deals should provide a boost to biotech exchange-traded funds, making the SPDR S&P Biotech ETF and the iShares Biotechnology ETF worth watching.
If the current M&A frenzy continues, the biopharma industry could top $250 billion in deal value this year, according to PitchBook data. That compares to $201.3 billion in 2025, and would mark the strongest period since 2019, when expiring patent protections and a rush to rebuild pipelines drove a multibillion-dollar acquisition spree across the sector.
This time around, similar dynamics are at play. Haider points to several factors powering the momentum: impending patent cliffs, a favorable regulatory environment, and an effort to bolster pipelines with recent innovations from smaller biotechs.
And established biopharmaceutical firms have the cash to do it. They are eager to put that money to work in an increasingly competitive environment, where such a strategy increases the likelihood of getting cutting-edge products to market.
"These companies are really well-capitalized. When we use our standard 'firepower formula,' which is two times, 2 1/2 times debt to Ebitda, we get to about $650 billion across the industry in firepower," Haider says. "That's a lot of money to slosh around. And you don't get paid for firepower on your balance sheet." Ebitda stands for earnings before interest, taxes, depreciation, and amortization.
A possible AstraZeneca-Bristol Myers deal reflects all of these dynamics. AstraZeneca also has signaled growing global ambitions and an increasing focus on the U.S. market, according to Barclays analysts. The company added a direct share listing on the New York Stock Exchange in February, following drug-pricing agreements with the Trump administration a few months earlier.
Bristol Myers, meanwhile, faces a critical patent cliff in 2028, when key protections begin to expire for two of its major blockbusters: immunotherapy Opdivo and blood thinner Eliquis, which is co-developed with Pfizer. The company is leaning on newer drugs to replace lost revenue, with its burgeoning growth portfolio showing strength in the latest quarter. Analysts say AstraZeneca has a comparatively stronger pipeline and less patent expiration pressure.
Wall Street isn't sold. While smaller bolt-on acquisitions are routine in biopharma, megamergers have become far less common. In addition to regulatory scrutiny over the two companies' shared oncology focus, the sheer complexity of integrating them could create a major financial drain.
Nonetheless, the industrywide shopping spree is far from over. Midsize targets continue to draw plenty of interest, with former Johnosn & Johnson partner Arrowhead Pharmaceuticals regularly popping up in takeover chatter, and cancer-drug developer Revolution Medicines emerging as a top takeover candidate on the back of its strong pipeline.
In an industry relentlessly chasing innovation, Big Pharma has both the motive and the money to keep buying -- and investors stand to reap the benefits.
Comments